恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.06.005

摘要/Abstract

摘要： 目的探讨恩替卡韦联合α-干扰素(IFN-α)治疗慢性乙型肝炎(CHB)患者的疗效。方法 2019年5月～2022年3月我院收治的69例CHB患者被随机分为A组35例和B组34例,分别给予恩替卡韦联合IFN-α或单纯恩替卡韦治疗,观察12个月。采用荧光定量PCR法检测血清HBV DNA载量,采用放射免疫分析法检测血清透明质酸 (HA) 、层粘连蛋白(LN) 、IV型胶原(CIV) 和III型前胶原(PIIIP) 水平,采用ELISA法检测血清人尾肢同源蛋白2(Pygo2)、核转录因子κB (NF-κB)、转化生长因子-β(TGF-β)、肿瘤坏死因子-α(TNF-α)和白介素-6(IL-6) 水平。结果在治疗6个月和12个月末,A组血清ALT复常率分别为88.6%和94.3%,显著高于B组的67.6%和73.5%(P＜0.05),而两组血清HBV DNA阴转率无显著性差异(分别为91.4%对91.2,和97.1%对91.2%,P>0.05);在治疗12个月末,A组血清ALT和AST水平分别为(51.4±6.4)U/L和(47.5±5.2)U/L,显著低于B组【分别为(67.7±7.4)U/L和(61.9±6.7)U/L,P＜0.05】;A组血清HA和PC-Ⅲ水平分别为(93.9±21.4)ng/mL和(87.3±15.8)ng/mL,显著低于B组【分别为(125.3±24.3)ng/mL和(108.9±14.7)ng/mL,P＜0.05】;A组血清NF-kB、TGF-β和Pygo2水平分别为(1.1±0.3)pg/mL、(3.4±1.1)pg/mL和(41.9±4.6)μg/L,显著低于B组【分别为(1.6±0.4)pg/mL、(4.3±1.3)pg/mL和(54.6±5.2)μg/L,P<0.05】。结论应用恩替卡韦联合IFN-α治疗CHB患者较单用恩替卡韦治疗可以获得较好的短期疗效,提高肝功能指标复常率,降低血清肝纤维化指标,降低机体炎性反应,但联合短效IFN-α治疗对血清学应答的影响还需要观察。

关键词: 慢性乙型肝炎, α-干扰素, 恩替卡韦, 细胞因子, 治疗

Abstract: Objective This study was conducted to observe the virologic and biochemical response to entecavir and interferon-α(IFN-α) combination therapy in patients with chronic hepatitis B (CHB). Methods 69 patients with CHB were enrolled in our hospital between May 2019 and March 2022, and they were divided randomly into group A (n=35) and group B (n=34), receiving entecavir and FN-α combination or entecavir alone therapy for 12 months. Serum HBV DNA loads were detected by fluorescence quantitative PCR, and serum hyaluronic acid (HA), laminin (LN), collagen IV (CIV) and procollagen III (PIIIP) levels were detected by radioimmunoassay. Serum human pygopus homolog 2 (Pygo2), nuclear transcription factor κB (NF-κB), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels were detected by enzyme-linked immunosorbent assay. Results At the end of six and twelve month treatment, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) normalization rates in group A were 88.6% and 94.3%, both significantly higher than 67.6% and 73.5%(P＜0.05) in group B, while there was no significant difference as respect to serum HBV DNA loss (91.4% vs. 91.2, and 97.1% vs. 91.2%, respectively, P>0.05) between the two groups; at the end of twelve month treatment, serum ALT and AST levels in group A were (51.4±6.4)U/L and (47.5±5.2)U/L, significantly lower than [(67.7±7.4)U/L and (61.9±6.7)U/L, respectively, P＜0.05] in group B; serum HA and PC-Ⅲ levels in group A were (93.9±21.4)ng/mL and (87.3±15.8)ng/mL, significantly lower than [(125.3±24.3)ng/mL and (108.9±14.7) ng/mL, respectively, P＜0.05] in group B; serum NF-kB, TGF-β and Pygo2 levels in group A were (1.1±0.3)pg/mL, (3.4±1.1)pg/mL and (41.9±4.6)μg/L, all significantly lower than [(1.6±0.4)pg/mL,(4.3±1.3)pg/mL and (54.6±5.2)μg/L, respectively, P<0.05] in group B. Conclusion In clinical practice, the combination of entecavir and IFN-α treatment in dealing with patients with CHB could alleviate liver function injury, decrease serum liver fibrosis index and reduce inflammatory reaction, and have a good short-term efficacy.

Key words: Hepatitis B, Entecavir, Interferon-α, Cytokines, Therapy

宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.

Song Tao, Xu Min, Dang Zilong, et al. Virologic and biochemical response to entecavir and interferon-α combination therapy in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(6): 785-788.

参考文献

[1] Nagura Y, Matsuura K, Iio E,et al. Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. PLoS One,2022,17(2):e0263844.
[2] Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol,2021,75(5):1104-1115.
[3] Fan R,Niu J, Ma H,et al. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther,2021,54(3):329-338.
[4] El-Nahaas SM, Rady NH, Malek S,et al. Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents. Eur J Gastroenterol Hepatol,2021,33(1):e335-e340.
[5] Jung CY, Kim HW,Ahn SH,et al. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B. Liver Int,2022,42(5):1017-1026.
[6] 陈儒,王彦芝,郭淑苗.滋肾柔肝汤联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效及对肝纤维化指标的影响.中药材,2021,44(4):994-997.
[7] Kalay Yildizhan I, Akay BN, Aygun M,et al. Treatment of lymphomatoid papulosis resistant to methotrexate therapy with intralesional interferon-alpha-2a. Dermatol Ther,2021,34(4):e14971.
[8] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):V-XVI.
[9] Ben Selma W,Laribi AB, Alibi S,et al. Association of an IFN-γ variant with susceptibility to chronic hepatitis B by the enhancement of HBV DNA replication. Cytokine,2021,14(3):155525.
[10] Lee SK, Kwon JH, LeeSW,et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int,2021,41(2):288-294.
[11] Chen S, Zhou J, WuX,et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.Hepatol Int,2021,15(3):611-620.
[12] Su F, Berry K,Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut,2021,70(2):370-378.
[13] Tadokoro T, Fujita K, TakumaK,et al. Peg-IFNα-2a contributed to HBs antigen seroclearance in a patient with chronic hepatitis B administered nucleic acid analogs: A three-year follow-up. Intern Med,2021,60(12):1835-1838.
[14] Liu Y, Chen R, Liu W, et al. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.Antivir Res,2021, 189(1):105058.
[15] Ren P, Li H, Huang Y,et al. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res,2021,19(4):105163.
[16] Toyoda T, Wang Y, WenY,et al. Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. Anal Biochem,2020,59(7):113642.
[17] Zhang Q, Zhang L, XingY,et al. Comparison of the 48-week efficacy of lamivudine plus adefovir or entecavir monotherapy in patients with HBeAg negative hepatitis following lamivudine treatment failure. Acta Gastroenterol Belg,2019,82(1):31-34.
[18] 郑志恒,李维筠,回振宇,等. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化.实用肝脏病杂志,2021,24(1):19-22.
[19] Bekcibasi M, Deveci O, Oguz A,et al. Serum TNF-α, IL-1β, and IL-6 levels in chronic HBV-infected patients. Int J Clin Pract,2021,75(8):e14292.
[20] 尚鹏程,许娇,钟晶,等.干扰素治疗前后慢性乙型肝炎患者外周血淋巴细胞和中性粒细胞表面CD64表达变化观察.山东医药,2023,63(3):22-25.

恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*

Virologic and biochemical response to entecavir and interferon-α combination therapy in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[3]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[4]	张玥, 宁玲, 李文渊, 郑晓玮, 刘洪涛, 张振华, 李磊. 血清HBsAg阳性者接受肾移植术120周预后随访报告^*[J]. 实用肝脏病杂志, 2023, 26(6): 797-800.
[5]	曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.
[8]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[9]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[10]	邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.
[11]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[12]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[13]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[14]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[15]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.